These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 23727412)
1. The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. Filson CP; Hollingsworth JM; Clemens JQ; Wei JT J Urol; 2013 Dec; 190(6):2153-60. PubMed ID: 23727412 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. Kim HJ; Sun HY; Choi H; Park JY; Bae JH; Doo SW; Yang WJ; Song YS; Ko YM; Kim JH PLoS One; 2017; 12(1):e0169248. PubMed ID: 28072862 [TBL] [Abstract][Full Text] [Related]
3. Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. Pang R; Zhou XY; Wang X; Wang B; Yin XL; Bo H; Jung JH Cochrane Database Syst Rev; 2021 Feb; 2(2):CD012336. PubMed ID: 33567116 [TBL] [Abstract][Full Text] [Related]
4. Safety of anticholinergics in patients with benign prostatic hyperplasia. Athanasopoulos A; Mitropoulos D; Giannitsas K; Perimenis P Expert Opin Drug Saf; 2008 Jul; 7(4):473-9. PubMed ID: 18613810 [TBL] [Abstract][Full Text] [Related]
5. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967 [TBL] [Abstract][Full Text] [Related]
6. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. Logan YT; Belgeri MT Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387 [TBL] [Abstract][Full Text] [Related]
7. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Blake-James BT; Rashidian A; Ikeda Y; Emberton M BJU Int; 2007 Jan; 99(1):85-96. PubMed ID: 17026588 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615 [TBL] [Abstract][Full Text] [Related]
9. Combination treatment for male lower urinary tract symptoms with anticholinergic and alpha-blockers. Gomelsky A; Kelly EF; Dalton DC Curr Opin Urol; 2018 May; 28(3):277-283. PubMed ID: 29432226 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. Yan H; Zong H; Cui Y; Li N; Zhang Y J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088 [TBL] [Abstract][Full Text] [Related]
12. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Zhang J; Li X; Yang B; Wu C; Fan Y; Li H World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of an α Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827 [TBL] [Abstract][Full Text] [Related]
16. [Pharmacological treatment of benign prostatic hyperplasia]. Oelke M; Martinelli E Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726 [TBL] [Abstract][Full Text] [Related]
17. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F; Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505 [TBL] [Abstract][Full Text] [Related]
18. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study. Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190 [TBL] [Abstract][Full Text] [Related]
19. The role of combination medical therapy in benign prostatic hyperplasia. Greco KA; McVary KT Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123 [TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms. Park YH; Kim TH; Lee SW; Chung BH; Cho JS; Lee JY Low Urin Tract Symptoms; 2017 May; 9(2):75-81. PubMed ID: 28394492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]